Online inquiry

IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11784MR)

This product GTTS-WQ11784MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11784MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7655MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ15311MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ3962MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ15067MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ2281MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ2716MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG103
GTTS-WQ10100MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ9669MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW